Savara (NASDAQ:SVRA) Stock Price Down 6.4%

Savara Inc (NASDAQ:SVRAGet Free Report)’s stock price dropped 6.4% during trading on Monday . The stock traded as low as $3.61 and last traded at $3.63. Approximately 449,063 shares traded hands during trading, a decline of 50% from the average daily volume of 899,262 shares. The stock had previously closed at $3.88.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Savara in a research report on Monday, May 13th. Evercore ISI cut their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, May 16th. Piper Sandler boosted their price target on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. JMP Securities reissued a “market outperform” rating and set a $8.00 price target on shares of Savara in a research report on Monday, May 6th. Finally, Oppenheimer boosted their price target on shares of Savara from $9.50 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 21st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $9.17.

View Our Latest Report on SVRA

Savara Stock Performance

The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90. The stock’s fifty day moving average price is $4.41 and its 200-day moving average price is $4.65. The company has a market capitalization of $508.54 million, a P/E ratio of -9.92 and a beta of 0.70.

Savara (NASDAQ:SVRAGet Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, research analysts anticipate that Savara Inc will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Superstring Capital Management LP acquired a new position in Savara in the 4th quarter valued at about $3,827,000. Adage Capital Partners GP L.L.C. grew its stake in Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after buying an additional 1,874,000 shares during the last quarter. Polar Capital Holdings Plc acquired a new position in Savara in the 3rd quarter valued at about $3,780,000. Jennison Associates LLC grew its stake in Savara by 128.0% in the 4th quarter. Jennison Associates LLC now owns 8,815,358 shares of the company’s stock valued at $41,432,000 after buying an additional 4,948,596 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Savara in the 4th quarter valued at about $74,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.